

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Design and Biological Evaluation of New Mechanismbased Inhibitors of S-Adenosyl-L-homocysteine Hydrolase

Stanislaw F. Wnuk^a; Chong-Sheng Yuan^b; Ronald T. Borchardt^b; J. Robins Morris^c

^a Department of Chemistry, Florida International University, Miami, FL ^b Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT ^c Department of Biochemistry, University of Kansas, Lawrence, KS

To cite this Article Wnuk, Stanislaw F. , Yuan, Chong-Sheng , Borchardt, Ronald T. and Morris, J. Robins(1999) 'Design and Biological Evaluation of New Mechanismbased Inhibitors of S-Adenosyl-L-homocysteine Hydrolase', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 595 — 596

To link to this Article: DOI: 10.1080/15257779908041506

URL: <http://dx.doi.org/10.1080/15257779908041506>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

DESIGN AND BIOLOGICAL EVALUATION OF NEW MECHANISM-BASED INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE


Stanislaw F. Wnuk,^{§,*} Chong-Sheng Yuan,[†] Ronald T. Borchardt,[†] and Morris, J. Robins[‡]

[§]Department of Chemistry, Florida International University, Miami, FL 33199, [†]Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, 84602, and [‡]Department of Biochemistry, University of Kansas, Lawrence, KS 66047

ABSTRACT: Geminal dihalohomovinyl **2** and haloacetylenic **4** analogs derived from adenosine were prepared. These compounds exhibited type II (covalent) mechanism-based inactivation of *S*-adenosyl-L-homocysteine hydrolase.

The cellular enzyme *S*-adenosyl-L-homocysteine hydrolase effects hydrolytic cleavage of *S*-adenosyl-L-homocysteine, a potent inhibitor of crucial transmethylation enzymes, to adenosine and L-homocysteine. A number of inhibitors which function as substrates for the "3'-oxidative activity" of the enzyme and convert the enzyme from its active form (NAD⁺) to its inactive form (NADH, type I inhibition) have been prepared.¹ Inhibitors which function as substrates for the "5'/6'-hydrolytic activity" were also synthesized² which included oxime derivatives of adenosine 5'-carboxaldehydes and their 2'- and 3'-deoxy analogues.³

Geminal (dihalohomovinyl)adenosines **2** were designed as putative new substrates for the hydrolytic activity of AdoHcy hydrolase.⁴ Analogues **2** have been synthesized from protected Ado-5'-carboxaldehyde with the Corey-Fuchs procedure⁵ [CBr₃X (X = Br or F)/PPh₃/Zn] and successive deprotections of **1**.^{4a} Treatment of **1** (X = Br) with excess BuLi gave the acetylenic derivative **3** (53%).^{6,7}



Treatment of **3** with *N*-iodosuccinimide and catalytic AgNO_3 ⁸ resulted in efficient 6'-iodination. Sequential removal of the 6'-*N*-benzoyl (NH_3/MeOH) and isopropylidene [$\text{CF}_3\text{CO}_2\text{H}/\text{H}_2\text{O}$] groups gave the iodoacetylene derivative **4a** (42% from **3**). Analogously, treatment of **3** with *N*-bromosuccinimide gave bromoacetylene derivative **4d**.

Addition of an enzyme-sequestered water molecule across the 5',6'-double bond of bromo(fluoro)homovinyl analogue **2b** followed by loss of bromide could result in the formation of a reactive homoAdo 6'-carboxyl fluoride at the active site of AdoHcy hydrolase.^{4b} Nucleophilic attack by proximal amino acid functionalities causes type II (covalent binding) inhibition of the AdoHcy hydrolase. Similarly, addition of water across the 5',6'-triple bond of haloacetylenes **4** followed by tautomerization of the hydroxyvinyl intermediates could generate acyl halides (C6' hydroxyl attack) and/or α -halomethyl ketones (C5' hydroxyl attack) at the enzyme active site. Compound **2** and **4** are the first examples of type II inhibitors that are activated by the "hydrolytic activity" of the enzyme without prior oxidation at C3'.

REFERENCES

1. Yuan, C.-S.; Liu, S.; Wnuk, S. F.; Robins, M. J.; Borchardt, R. T. *Advances in Anti-viral Drug Design*; De Clercq, E., Ed; JAI Press: Greenwich, 1996; Vol. 2, pp 41–88.
2. (a) McCarthy, J. R.; Jarvi, E. T.; Matthews, D. P.; Edwards, M. L.; Prakash, N. J.; Bowlin, T. L.; Mehdi, S.; Sunkara, P. S.; Bey, P. *J. Am. Chem. Soc.* **1989**, *111*, 1127–1128. (b) Yuan, C.-S.; Yeh, J.; Liu, S.; Borchardt, R. T. *J. Biol. Chem.* **1993**, *268*, 17030–17037. (c) Wnuk, S. F.; Yuan, C.-S.; Borchardt, R. T.; Balzarini, J.; De Clercq, E.; Robins, M. J. *J. Med. Chem.* **1994**, *37*, 3579–3587. (d) Yuan, C.-S.; Wnuk, S. F.; Liu, S.; Robins, M. J.; Borchardt, R. T. *Biochemistry* **1994**, *33*, 12305–12311.
3. (a) Wnuk, S. F.; Yuan, C.-S.; Borchardt, R. T.; Balzarini, J.; De Clercq, E.; Robins, M. J. *J. Med. Chem.* **1997**, *40*, 1608–1618. (b) Huang, H.; Yuan, C.-S.; Wnuk, S. F.; Robins, M. J.; Borchardt, R. T.; *Arch. Biochem. Biophys.* **1997**, *343*, 109–117.
4. (a) Wnuk, S. F.; Mao, Y.; Yuan, C.-S.; Borchardt, R. T.; Andrei, J.; Balzarini, J.; De Clercq, E.; Robins, M. J. *J. Med. Chem.* **1998**, *41*, 3078–3083. (b) Yuan, C.-S.; Wnuk, S. F.; Robins, M. J.; Borchardt, R. T. *J. Biol. Chem.* **1998**, *273*, 18191–18197.
5. Corey, E. J.; Fuchs, P. L. *Tetrahedron Lett.* **1972**, 3769–3772.
6. Robins, M. J.; Wnuk, S. F.; Yang, X.; Yuan, C.-S.; Borchardt, R. T.; Balzarini, J.; De Clercq, E. *J. Med. Chem.* in press.
7. Parry, R. J.; Muscate, A.; Askonas, L. J. *Biochemistry* **1991**, *30*, 9988–9997.
8. Hofmeister, H.; Annen, K.; Laurent, H.; Wiechert, R. *Angew. Chem., Int. Ed. Engl.* **1984**, *23*, 727–729.